While the World Is in a New Drug War… Korean Pharmaceutical Companies’ R&d Investment Remains Stagnant

조선일보

Lean Right

Factuality

Ownership

Research and development (R&D) investment by the top five domestic pharmaceutical companies has been found to be stagnating in the 1 trillion won range. With the industry atmosphere unsettled due to drug price cuts, each company has a wide range of calculations. Some are taking a straightforward approach by focusing on new drug development, while others are seeking new revenue sources through business diversification.